Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The new compound may be a safer alternative to finasteride for prostate protection.

5α-Reductase inhibitors do not consistently increase testosterone levels in the blood.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

A new compound effectively inhibits human 5α-reductase 1.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.

Finasteride, a medication, is being re-evaluated for its effects and uses.

The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.

Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.

5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.

Scientists found new, better-working inhibitors for a hormone-related enzyme.

Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.

New compounds may soon be tested to treat excessive hair growth in women.

Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.

Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.

Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.

Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.

Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

5ARIs lower PSA levels, but other tests are needed to avoid missing aggressive prostate cancer.

Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.